Navigation Links
Survival Data for Avicena's Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
Date:10/18/2007

PALO ALTO, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, announced today that data related to the Company's Amyotrophic Lateral Sclerosis (ALS) drug candidate, AL-02, will be presented at the 18th International Symposium on ALS/MND which will be held on December 1-3, 2007, in Toronto, Canada. The poster presentation by Allitia DiBernardo, M.D. of Massachusetts General Hospital will discuss a pooled analysis of survival data from three randomized, placebo-controlled studies. Results suggest a trend towards increased survival in patients taking AL-02.

The combined analysis examined three trials and included a total of 386 patients. The three trials were conducted by the Northeast ALS Consortium (NEALS), Carolinas Medical Center and Utrecht University. The pooled analysis showed an increase of 1.47-fold in median survival compared to results in patients taking a placebo. Certain portions of these data were presented to the FDA and formed the basis for Avicena's intent to initiate a confirmatory Phase III trial in 2008. This study will evaluate AL-02's effect on the primary endpoint of median survival and secondary endpoints of ALS functional scores.

"These data points support AL-02's positive effect on the survival rate of ALS patients," stated Belinda Tsao-Nivaggioli, Chairman and C.E.O. of Avicena. "We are very encouraged by these results and we will continue to advance AL-02 towards commercialization, as well as our drug candidates for Parkinson's and Huntington's disease. AL-02 will be the Company's third late-stage drug candidate."

ABOUT ALS

ALS is a neurodegenerative disease that attacks the motor neurons of the brain and spinal cord that are responsible for voluntary muscle movement. As these motor neurons degenerate, their ability to send impulses to the muscle fibers is c
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... PHILADELPHIA , April 24, 2015  Lannett Company, ... has amended and increased its five-year revolving credit facility ... includes an accordion feature that will allow the company ... an additional $30.0 million, subject to securing additional commitments ... date of the credit facility remains December 18, 2018. ...
(Date:4/23/2015)... 24, 2015  AbbVie (NYSE: ABBV ) has ... has accepted its New Drug Application (NDA) and granted ... antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin ... with chronic genotype 4 (GT4) hepatitis C virus (HCV) ... interferon-free therapy being evaluated by the FDA for patients ...
(Date:4/23/2015)... Pharmaceuticals plc (Nasdaq: JAZZ ) today announced that ... on Thursday, May 7, 2015, after the close of ... audio webcast immediately following the announcement at 4:30 p.m. ... results and provide a business and financial update. ... via the Investors & Media section of the Jazz ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 2
... 2010 TechniScan, Inc. (OTC Bulletin Board: ... development and commercialization of an automated breast ultrasound imaging system, ... TechniScan entered into amendments with each note holder, effective as ... its entire portfolio of secured convertible promissory notes from October ...
... 8, 2010 Arstasis is pleased to announce that ... Registry Evaluating Closure Following Access with the Arstasis One ... anticipated to enroll up to 500 patients in at ... is to observe the clinical safety and effectiveness of ...
Cached Medicine Technology:TechniScan, Inc. Announces Restructuring of Convertible Debt 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 2Seven U.S. Medical Centers Commence Study to Change Femoral Artery Cath Lab Access with the First Alternative to the Seldinger Technique in 51 Years 3
(Date:4/24/2015)... New York (PRWEB) April 24, 2015 ... to move forward in the federal multidistrict litigation ... Carolina. According to court documents, the parties involved ... on April 16th detailing, among other things, preparation ... notes that counsel for both plaintiffs and defendants ...
(Date:4/24/2015)... 24, 2015 The first step to ... mind. , For meditation and yoga teacher Stine Koppernæs, ... been invaluable tools that allow her to experience more ... has been a teacher since 2006, and through the ... state of being. , “I love sharing this way ...
(Date:4/24/2015)... 24, 2015 Anchor Health Administrators (Anchor), ... Professionals, today announced their exclusive agreement with LTC Solutions ... Care Insurance distribution partner. , Anchor has more than ... Insurance benefits for associations, and is currently the designated ... Long Term Care Insurance member benefit. , “I am ...
(Date:4/24/2015)... Fla. (PRWEB) April 24, 2015 “Kind,” ... healer” were among the ways Denise Weiner described pediatric ... who cared for her daughter, Alexa, during her five-year ... brain resections, a bone marrow transplant and numerous experimental ... house to visit Alexa when she was not in ...
(Date:4/24/2015)... National Access Cannabis (NAC), Canada’s ... medical cannabis, is taking a leadership role in ensuring ... , NAC is the first to back mdBriefCase Group ... NAC will be providing 300 healthcare professionals with free ... help Canadians gain safe and responsible access to medical ...
Breaking Medicine News(10 mins):Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 2Health News:Federal Lipitor Lawsuits Progress, as New Status Report Details Preparation for Upcoming Bellwether Trials 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 2Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 3Health News:CURE™ Magazine Names Pediatric Nurse Laura Vasquez from Children’s Hospital Los Angeles As Extraordinary Healer™ of 2015 4Health News:National Access Cannabis Gives 300 Canadian Healthcare Professionals Access to Medical Cannabis Certificate Program 2
... Awareness,Week approaches, 2009 brings yet another year of unhealthy ... Americans, including men and,boys. , ... eating,disorders is so important because hundreds of thousands of ... even consider an eating,disorder as a diagnosis for a ...
... and ,e-commerce feature to company Web site - www.geritrex.com . ... ... -- The Geritrex Corporation, a privately held pharmaceutical company that offers ... business. Founded by CEO and registered pharmacist Anthony Madaio, Geritrex ...
... tests for devastating conditions, report says , , WEDNESDAY, Feb. 18 ... three babies in the United States was born in a ... of conditions. But by the end of 2008, all 50 ... rules requiring newborn screening for at least 21 disorders, a ...
... RIVER, N.Y., Feb. 18 Tesia-PCI has successfully ... with United Concordia Companies, Inc., a national dental ... took just over two months from plan to ... experience and expertise helped United Concordia to avoid ...
... was announced today that,Medizone International,s (Pink Sheets: MZEI) ... direction of Dr. Michael E.,Shannon of the Canadian ... President of the Canadian Foundation for Global Health. ... Medizone International and is the Company,s,Director of Medical ...
... continues to present its myriad of challenges, SunStone ... cost cutting measures including cutbacks in capital projects, ... direct patient contact such as marketing, community, and ... easier layers to peel in these expense reduction ...
Cached Medicine News:Health News:Remuda Ranch Seeks to Increase Awareness of Eating Disorders Among Males During National Eating Disorders Awareness Week (NEDAW), February 22-28, 2009 2Health News:A "Healthy" Company - Geritrex Celebrates Its 30 Year Anniversary with New Rebranding Effort and Expanding Distribution Channels 2Health News:Newborn Screenings Now Required Across U.S. 2Health News:Newborn Screenings Now Required Across U.S. 3Health News:National Dental Insurer United Concordia Successfully Launches Real-Time Claims Processing with Tesia-PCI 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 2Health News:The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc. 3Health News:The Marketing Enigma 2
... occlusive wrap than VICRYL knitted mesh. Especially ... be contained. Predictable absorption. Polyglactin 910 has ... nonpyrogenic. ,VICRYL (polyglactin 910) woven mesh is ... glycolide and lactide, derived respectively from glycolic ...
... Line Reinforcement Material is a safe, ... air leaks and as such, the ... biocompatible, ePTFE material requires no pretreatment ... load and fire and the material's ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... ProLite Ultra™, the next generation of thin ... hernia surgery and general soft tissue repair. ... better handling and more flexible polyproplylene mesh, ... ProLite Ultra. Its unique Litemesh™ polypropylene microfilament ...
Medicine Products: